Can a second drug help scleroderma patients breathe easier?
NCT ID NCT07491523
First seen Mar 25, 2026 · Last updated May 23, 2026 · Updated 6 times
Summary
This study looks at whether adding an anti-fibrotic drug to standard double immunosuppression can better preserve lung function in people with scleroderma-related interstitial lung disease (ILD). About 35 adults will be followed for 12 months with regular breathing tests. The goal is to see if the combination slows lung damage better than immunosuppression alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SSC-SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of patras
RECRUITINGPátrai, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.